IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases

被引：0

作者：

Divya Thiagarajan

Nina Oparina

Susanna Lundström

Roman Zubarev

Jitong Sun

Marta Alarcon-Riquelme

Johan Frostegård

机构：

[1] Karolinska Institutet,Unit of Immunology and Chronic Disease, Institute of Environmental Medicine

[2] Karolinska Institutet,Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics

[3] GENYO,Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique

[4] Center for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Government,Servicio Cantabro de Salud

[5] Parque tecnolуgico de la salud,Hospital Clinic I Provicia

[6] Referral Center for Systemic Autoimmune Diseases,Servicio Andaluz de Salud

[7] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano,Servicio Andaluz de Salud

[8] Centre Hospitalier Universitaire de Brest,Servicio Andaluz de Salud

[9] Hospital de la Cavale Blanche,Servicio Andaluz de Salud

[10] Université catholique de Louvain,undefined

[11] Centro Hospitalar do Porto,undefined

[12] Hospital Universitario Marqués de Valdecilla,undefined

[13] Institut d’Investigacions Biomèdiques August Pi i Sunyer,undefined

[14] Katholieke Universiteit Leuven,undefined

[15] Klinikum der Universitaet zu Koeln,undefined

[16] Medizinische Hochschule Hannover,undefined

[17] Medical University Vienna,undefined

[18] Hospital Universitario Reina Sofía Córdoba,undefined

[19] Complejo hospitalario Universitario de Granada (Hospital Universitario San Cecilio),undefined

[20] Complejo hospitalario Universitario de Granada (Hospital Virgen de las Nieves),undefined

[21] Hospital Regional Universitario de Málaga,undefined

[22] Università degli studi di Milano,undefined

[23] Hospitaux Universitaires de Genève,undefined

[24] University of Szeged,undefined

[25] Charite,undefined

[26] Andalusian Public Health System Biobank,undefined

来源：

Scientific Reports | / 10卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic sclerosis (SSc, 331), Sjögren’s syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was determined by flow cytometry. The maximal difference between cases and controls was shown for MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, Anti-PC is decreased in MCTD and also in SLE, SjS and SSc but not in other studied diseases. Anti-PC may thus differentiate between these. In contrast, anti-MDA did not show these differences between diseases studied. Anti-PC level is negatively correlated with CV in the patient group cohort. In contrast to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic and therapeutic implications, one possibility being active or passive immunization with PC in some rheumatic conditions.

引用

共 76 条

[1]

Gabriel SE(2009)Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases Arthritis Res Ther 11 229-476

[2]

Michaud K(2010)Geoepidemiology of autoimmune rheumatic diseases Nat Rev Rheumatol 6 468-207

[3]

Shapira Y(2009)Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases J Autoimmun 33 197-169

[4]

Agmon-Levin N(2000)Epidemiology of cardiovascular disease in systemic lupus erythematosus Lupus 9 166-1785

[5]

Shoenfeld Y(2005)Atherosclerosis in patients with autoimmune disorders Arterioscler Thromb Vasc Biol 25 1776-1893

[6]

Cooper GS(2001)Risk factors for cardiovascular disease in systemic lupus erythematosus Circulation 104 1887-3347

[7]

Bynum ML(2005)Accelerated atherosclerosis in autoimmune rheumatic diseases Circulation 112 3337-248

[8]

Somers EC(2011)Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity Circ Res 108 235-52

[9]

Aranow C(2012)Immunomodulatory properties of ES-62, a phosphorylcholine-containing glycoprotein secreted by Acanthocheilonema viteae Endocrine, metabolic & immune disorders drug targets 12 45-129

[10]

Ginzler EM(1999)Phosphorylcholine: friend or foe of the immune system? Immunol Today 20 125-59

← 1 2 3 4 5 6 7 8 →